RELATIONSHIP BETWEEN SPHINGOMYELIN LEVELS AND PARKINSON'S DISEASE: EVIDENCE AND PERSPECTIVES
DOI:
https://doi.org/10.47820/recima21.v5i9.5632Keywords:
Neurodegenerative Diseases. Metabolism. Lipids.Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease (ND) after Alzheimer's disease (AD). Studies over two decades have revealed the association between PD and defects in lysosomal sphingolipid metabolism. Objectives: to identify if there are changes in sphingomyelin in Parkinson's disease. Materials and methods: This is an integrative review, in which the guiding question was “Are sphingomyelins altered in Parkinson's disease?”. The search for articles was carried out in PubMed and Google Scholar using the terms “sphingomyelin” and “parkinson's disease”, combined with the Boolean operator “AND”. Results and discussion: Sphingomyelin belongs to a class of lipids called sphingolipids. Disruption in the sphingomyelin signaling pathway is associated with several neurodegenerative disorders, including Parkinson's disease. Serum lipids were significantly altered between those with and without Parkinson's disease. Sphingomyelin is essential for the myelin sheath, impulse transmission, synaptic plasticity, neurotransmitter receptor localization, and integrity of the blood-brain barrier. Conclusion: we concluded in our study that sphingomyelin levels are reduced in Parkinson's disease.
Downloads
References
ALBI, Elisabetta et al. Lipids in the Brain. Frontiers in Neurology, v. 11, p. 712, 2020. DOI: https://doi.org/10.3389/fneur.2020.00712
ALESSENKO, Alice V.; ALBI, Elisabetta. Exploring sphingolipid implications in neurodegeneration. Frontiers in Neurology, v. 11, p. 437, 2020. DOI: https://doi.org/10.3389/fneur.2020.00437
BANARAS, Sanam et al. System level modeling and analysis of TNF-α mediated sphingolipid signaling pathway in neurological disorders for the prediction of therapeutic targets. Frontiers in Physiology, v. 13, p. 872421, 2022. DOI: https://doi.org/10.3389/fphys.2022.872421
CABREIRA, Veronica; MASSANO, JJAMP. Doença de Parkinson: Revisão clínica e atualização [Parkinson's disease: Clinical review and update]. Acta Med Port, v. 32, n. 10, p. 661-670, 2019. DOI: https://doi.org/10.20344/amp.11978
CHANG, Kuo-Hsuan et al. Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of Parkinson’s disease. Cells, v. 11, n. 3, p. 395, 2022. DOI: https://doi.org/10.3390/cells11030395
FERNÁNDEZ-IRIGOYEN, Joaquín et al. Alteration in the cerebrospinal fluid lipidome in Parkinson’s disease: a post-mortem pilot study. Biomedicines, v. 9, n. 5, p. 491, 2021. DOI: https://doi.org/10.3390/biomedicines9050491
FU, Yu Hong et al. Increased unsaturated lipids underlie lipid peroxidation in synucleinopathy brain. Acta Neuropathologica Communications, v. 10, n. 1, p. 165, 2022. DOI: https://doi.org/10.1186/s40478-022-01469-7
GALPER, Jasmin et al. Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease. Brain, v. 145, n. 10, p. 3472-3487, 2022. DOI: https://doi.org/10.1093/brain/awac176
GOÑI, Félix M. Sphingomyelin: What is it good for?. Biochemical and biophysical research communications, v. 633, p. 23-25, 2022. DOI: https://doi.org/10.1016/j.bbrc.2022.08.074
INDELLICATO, Rossella; TRINCHERA, Marco. The link between Gaucher disease and Parkinson’s disease sheds light on old and novel disorders of sphingolipid metabolism. International Journal of Molecular Sciences, v. 20, n. 13, p. 3304, 2019. DOI: https://doi.org/10.3390/ijms20133304
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Uso de gerenciador de referências bibliográficas na seleção dos estudos primários em revisão integrativa. Texto & Contexto-Enfermagem, v. 28, p. e20170204, 2019.
MINGIONE, Alessandra et al. Inhibition of ceramide synthesis reduces α-synuclein proteinopathy in a cellular model of Parkinson’s disease. International Journal of Molecular Sciences, v. 22, n. 12, p. 6469, 2021. DOI: https://doi.org/10.3390/ijms22126469
SIGNORELLI, Paola; CONTE, Carmela; ALBI, Elisabetta. The multiple roles of sphingomyelin in Parkinson’s disease. Biomolecules, v. 11, n. 9, p. 1311, 2021. DOI: https://doi.org/10.3390/biom11091311
SOUZA, Marcela Tavares de; SILVA, Michelly Dias da; CARVALHO, Rachel de. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), v. 8, p. 102-106, 2010. DOI: https://doi.org/10.1590/s1679-45082010rw1134
YANG, Rui et al. Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease. Parkinsonism & Related Disorders, p. 107071, 2024. DOI: https://doi.org/10.1016/j.parkreldis.2024.107071
Downloads
Published
How to Cite
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
